AIM ImmunoTech Inc. (AMEX:AIM) Q1 2023 Earnings Call Transcript
Operator: Hello, and welcome to the AIM ImmunoTech Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
Stay updated with breaking news from Thomas Equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Hello, and welcome to the AIM ImmunoTech Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
Operator: Hello, and welcome to the AIM ImmunoTech Inaugural Fiscal Year 2022 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
The study will evaluate type-1 polarized dendritic cell (αDC1) vaccine in combination with tumor-selective chemokine modulation comprised of...
AIM ImmunoTech leadership offers new details on a potential Phase II trial of Ampligen in long Covid patients with chronic fatigue.
AIM ImmunoTech has reported positive initial pilot study data from its Phase III trial of an investigational drug, Ampligen, for long Covid.